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Abstract 31 
 32 
Carbapenemase producing microorganisms are increasingly isolated and often associated with 33 
treatment failures and outbreaks. The need for reliable and timely detection and/or confirmation of 34 
carbapenemase production is paramount, therefore a real-time PCR assay targeting IMP, NDM, VIM, 35 
KPC and OXA-48-like carbapenemases was designed and validated. 36 
 37 
All available allele variants of the above carbepenmases were downloaded from the Beta-Lactamase 38 
DataBase (http://bldb.eu/), aligned with Clustal Omega and primers designed using Primer-BLAST. 39 
Real-time PCR monoplexes were optimized for the QuantStudio 6-Flex (Applied Biosystems) using the 40 
PowerUp SYBR Green Master Mix (Life Technologies) and validated using a panel of 204 characterised 41 
strains carrying a wide range of beta-lactamases, sometimes in combination. Melt-curve analysis was 42 
used to confirm positive results. 43 
 44 
The in silico approach allowed primers to be designed in conserved regions of the KPC and NDM 45 
alignments, while three primer sets for IMP and two for VIM were necessary to ensure amplification of 46 
the different variants. One primer set was designed for OXA-48-like, however it is unlikely to detect all 47 
variants. Expected results were obtained for all 204 tested strains, with 100% sensitivity and specificity. 48 
Melt-curve analysis showed consistent Tm results for KPC, NDM and OXA-48-like; differences were 49 
instead noted for IMP and VIM as likely consequence of higher variability in the PCR target regions. 50 
Inhibition was not observed. 51 
 52 
The assay is rapid, easy to perform and implement. It enables unequivocal detection of IMP, NDM, VIM, 53 
KPC and OXA-48-like carbapenemases even when more than one type is present simultaneously. 54 
  55 
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Introduction 56 
 57 
Carbapenems are amongst the last line of defence to treat serious bacterial infections. However, 58 
carbapenemases (i.e. enzymes able to inactivate carbapenems) are increasingly identified in both 59 
Enterobacteriales and non-fermenter Gram-negative isolates. Carbapenemase producing organisms 60 
(CPO) are frequently associated with treatment failure and outbreaks, with the latter worsened by the 61 
fact that carbapenemases are often present on mobile genetic elements and can therefore easily spread 62 
between different bacteria [1].  63 
In Wales, IMP, NDM, VIM, KPC and OXA-48-like (known as the “big five”) are the carbapenemases 64 
predominantly identified and consistent with those found in the rest of the UK: in particular, IMP, NDM, 65 
KPC and OXA-48-like in Enterobacteriales [2] and VIM in Pseudomonas species [3]. Phenotypic assays 66 
employing inhibitors for the different enzymes are available for the detection of some carbapenemases. 67 
For example IMP, NDM and VIM (Class B, metallo-ß-lactamase) enzymes are inhibited by chelating 68 
agents like ethylenediaminetetraacetic acid (EDTA) and dipicolinic acid (DPA), while KPC (class A ß-69 
lactamase) is  inhibited by boronic acid; an inhibitor for OXA-48-like (class D) -lactamases has not yet 70 
been identified, although temocillin resistance can be used as an indicator of its presence [4]. These 71 
phenotypic tests are both sensitive and specific predominantly for Enterobacteriales, while their 72 
performance is poor for Pseudomonas species [5, 6, 7]. Furthermore, these tests require 24hrs 73 
incubation to completion and can sometimes be difficult to interpret.  74 
Carbapenemase screening in Enterobacteriales is performed in Wales according to EUCAST criteria, 75 
i.e. meropenem inhibition zone < 28mm and/or meropenem MIC > 0.125 mg/mL [4] with isolates flagged 76 
as potential CPOs sent to the Specialist Antimicrobial Chemotherapy Unit (SACU), Cardiff (UK) for 77 
further investigation. For Acinetobacter and Pseudomonas species all carbapenem and carbapenem 78 
plus piperacillin/tazobactam resistant isolates are referred accordingly. In SACU, phenotypic 79 
confirmation of carbapenem resistance is performed and carbapenemase production investigated using 80 
Neo-SensitabsTM combination disks (ROSCO, Denmark) and MBL IP/IPI (Pseudomonas only) and MBL 81 
MP/MPI (Enterobacterales only) double ended E-Tests (bioMerieux, France), followed by in-house 82 
block-based PCR to confirm positive results.  83 
The number of isolates referred to SACU for carbapenemase confirmation doubled from approximately 84 
250 to 500 per year between 2015 and 2018, with an accompanying 100% rise in the number of CPO 85 
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confirmed per year (from 19 to 38). Nevertheless, the incidence in Wales (population approximately 86 
3,125,000 inhabitants estimated in June 2017 [8]) remains low when compared to data reported from 87 
other Countries [9]. Referral numbers are predicted to rise further as hospitals undertake more rigorous 88 
screening programmes to detect CPO in admission patients as per recommendations [10]. The increase 89 
in requests for carbapenemase confirmation plus the importance of rapidly detecting CPO for effective 90 
infection control management, demanded a development of the above described confirmatory approach 91 
adopted by SACU. These methods are time consuming, labour intensive and involve the use of the 92 
toxic and carcinogenic compound, ethidium bromide, to visualise PCR results by gel electrophoresis 93 
(although safer intercalating agents are available nowadays). The need for a more rapid and reliable 94 
approach has been identified with the aim to reduce the time to issue confirmatory reports and better 95 
assist clinicians and infection control teams. Real-time PCR is a well-established methodology for 96 
detecting genetic markers in bacteria. It can provide results much faster than block-based PCR and 97 
does not normally require the use of high risk reagents. Therefore, a real-time PCR assay based on 98 
SYBR Green chemistry has been designed to detect the “big five” carbapenemases and thoroughly 99 
validated using a large panel of previously characterised Gram-negative isolates. 100 
 101 
 102 
Materials and Methods 103 
 104 
Assay design 105 
IMP, NDM, VIM, KPC and OXA-48-like allele sequences were downloaded (as of December 2018) from 106 
the Beta-Lactamase DataBase [11] and aligned using Clustal Omega [12]. Alleles with less than 90% 107 
sequence identity to the rest of the alignment were excluded and separate primers were designed where 108 
a strain carrying them was available to the authors for in vitro testing.  Ten different primer sets per 109 
target were designed using Primer-BLAST [13] and then compared to the relevant alignment to identify 110 
the pair that at least in silico was able to amplify the highest number of alleles. Where necessary, 111 
degenerate bases (a maximum of 2 per primer) were added to cover non-conserved positions. Primer 112 
sequences and amplicon sizes are detailed in Table 1. 113 
 114 
Bacterial strains 115 
5 
 
A total of 204 previously characterised Gram-negative isolates from 19 different species isolated world-116 
wide were selected from the Authors’, Public Health England, NCTC and ATCC collections 117 
(Supplementary data). One hundred and thirteen carried one of the “big five” carbapenemases while 118 
22 carried two different markers simultaneously. The remaining 69 were negative for “big five” 119 
carbapenemases however some carried genes for other -lactamases (such as AmpC, CTX-M, GES, 120 
IMI, L1 & L2, OXA-10, OXA-23, OXA-51, OXA-58, TEM, SHV, SME, SPM and VEB). The 135 “big five” 121 
CPOs carried a total of 40 IMPs (including IMP-1, IMP-4, , IMP-6, IMP-7, IMP-8, IMP-10, IMP-11, IMP-122 
13, IMP-14, IMP-29 and IMP-62), 27 VIMs (including VIM-1, VIM-2, VIM-4, VIM-7, VIM-10, VIM-19 and 123 
VIM-29), 31 NDMs (NDM-1, NDM-3, NDM-4, NDM-5, NDM-7), 26 KPCs (including KPC-2, KPC-3, KPC-124 
4 and KPC-23) and 33 OXA-48-like markers (including OXA-48, OXA-181, OXA-204, OXA-232, OXA-125 
244 and OXA-245). 126 
  127 
After overnight aerobic growth on blood agar at 35±1°C, bacterial growth approximately equivalent to a 128 
third of a loopful (10 L loop) was re-suspended in 250 L of nuclease-free water and heat killed at 129 
100°C for 10 min. Supernatant was separated by centrifugation at 12,000 g for 2 min and diluted 1:20 130 
in nuclease-free water prior to testing. An extraction control (i.e. 250 L of nuclease-free water) was 131 
always included to discount cross contamination. A panel of seven strains was used as positive control 132 
in every experiment, namely Escherichia coli NCTC 13476 (IMPa), Serratia marcescens SACU 1212 133 
(IMPb), Pseudomonas aeruginosa SACU 1205 (IMPc), Klebsiella pneumoniae NCTC 13440 (VIM), 134 
Klebsiella pneumoniae NCTC 13443 (NDM), Klebsiella pneumoniae NCTC 13438 (KPC) and Klebsiella 135 
pneumoniae NCTC 13442 (OXA-48). 136 
 137 
Internal process control 138 
An assay detecting a 76 bp fragment of the green fluorescent protein, gfp from Aequorea victoria [14] 139 
was included to discount PCR inhibition. A custom-made plasmid (Eurofins, Germany) containing the 140 
entire gfp sequence (Genbank Accession: M62653) was diluted to a working concentration of 1 pmol/ L 141 
before being added to the GFP reaction mix. 142 
 143 
Real Time PCR 144 
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Monoplex PCR assays were optimized for the QuantStudio 6-Flex (Applied Biosystems) using the 145 
PowerUp SYBR Green MasterMix (Life Technologies) and Microamp Fast Optical 96-Well Reaction 146 
Plate 0.1 mL (Thermo-Fisher Scientific). Briefly, reactions were performed in a final volume of 10 L 147 
containing 5 L of MasterMix, 2.5 L of template, 2 L of PCR grade water and 0.5 L of relevant primer 148 
mix. The final concentration of each primer is listed in Table 2. The GFP reaction mix also contained 149 
0.5 L per reaction of pGFP [1 pmol/ L], with 1.5 L of PCR grade water to make 10 L final volume. 150 
After an initial uracil-DNA-glycosylase step at 50°C for 2 min, the Dual-LockTM DNA polymerase was 151 
activated at 95°C for 2 min followed by 35 cycles of denaturation at 95 °C for 1 sec and 152 
annealing/extension at 60°C for 20 sec. Amplification results were analysed with the threshold set at 153 
0.5 ΔRn for all targets and the baseline set between 5 and 15 cycles only for the GFP target. Melting 154 
curve analysis was performed as follows: 95°C for 15 sec (ramp rate = 1.6°C/sec), 60°C for 1 min (ramp 155 
rate = 1.6°C/sec) and 95°C for 15 sec (ramp rate = 0.15°C/sec) with fluorescence fluctuation analysed 156 
during the latter. 157 
 158 
 159 
Results 160 
 161 
In silico analysis 162 
 163 
The in silico approach allowed primers to be designed within 100% conserved regions of the KPC and 164 
NDM alignments.  For the remaining carbapenemases, a single primer set able to amplify all alleles, 165 
was not identified. Three primer sets (tested separately) were necessary to detect IMP variants and two 166 
sets (tested in the same tube) for VIM variants. One primer set was designed for the OXA-48-like group, 167 
however despite detecting the most common variants it is unlikely to detect OXA-54, OXA-436 and 168 
OXA-535 due the suboptimal sequence identity (i.e. < 90%) to the rest of the group. . Clustal alignments 169 
of PCR fragments with primers binding sites highlighted are available in the Supplementary data.  170 
 171 
Thirty-seven KPC variants were listed on the Beta-Lactamase DataBase, however two sets (i.e. KPC-172 
1 & KPC-2 and KPC-9 & KPC-23) were identical while KPC-20 was “assigned” but no sequence was 173 
available. Specific primers were designed in a conserved region of the remaining 34 KPC alleles. Primer 174 
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binding sites were 100% conserved and no single nucleotide polymorphisms (SNPs) were identified in 175 
the region between the primers. 176 
 177 
A specific primer set was designed in a conserved region of the alignment of all available 24 NDM 178 
variants, with no exclusion. Primer binding sites were 100% conserved and only one SNP (found in 179 
NDM-10) was identified in the region between the primers. 180 
 181 
Among the 79 described IMP variants, six (i.e. IMP-36, IMP-39, IMP-46, IMP-50, IMP-57 and IMP-65) 182 
appeared as “assigned” but no sequence was available. Moreover, IMP-8 and IMP-47 share identical 183 
sequence, consequently, the actual number of analysed variants was 72. Clustal analysis showed 184 
considerable sequence variability, therefore it was not possible to identify a single primer set able to 185 
detect all alleles. The Clustal generated tree was arbitrarily split in three sections (Figure 1) and a set 186 
of primers designed for each section (i.e. IMPa, IMPb and IMPc). Degenerate bases had to be inserted 187 
in all six primer sequences to ensure amplification of different variants.  188 
 189 
Among the 60 described VIM variants, VIM-21, VIM-22 and VIM-55 were “assigned” but no sequence 190 
was available. VIM-7 showed low sequence identity with the rest of the alleles (e.g. 81% identity with 191 
VIM-1), consequently it was excluded from the alignment. Specific primers were designed in a 192 
conserved region of the remaining 56 VIM alleles and one degenerate base was introduced in the 193 
forward primer. As previously mentioned, a separate set of primers was also designed specifically for 194 
VIM-7 as this variant was available to the authors for in vitro testing. 195 
 196 
Only OXA-48-like variants with a definitive assignment by NCBI (30 in total) were downloaded from the 197 
Beta-Lactamase DataBase (i.e. OXA-48, OXA-54, OXA-162, OXA-163, OXA-181, OXA-199, OXA-204, 198 
OXA-232, OXA-244, OXA-245, OXA-247, OXA-252, OXA-370, OXA-405, OXA-416, OXA-436, OXA-199 
438, OXA-439, OXA-484, OXA-505, OXA-514, OXA-515, OXA-517, OXA-519, OXA-535, OXA-538, 200 
OXA-546, OXA-547, OXA-566 and OXA-657). After Clustal analysis, OXA-54, OXA-436 and OXA-535 201 
were excluded from the alignment due to low sequence identity (84%, 84% and 85% respectively with 202 
OXA-48). In this instance specific primers were not designed as they were not available to the authors 203 
for in vitro testing. Primers for the remaining 27 OXA-48-like variants were designed in a conserved 204 
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region with one ambiguity introduced within the forward primer while the binding site of the reverse 205 
primer was 100% conserved. 206 
 207 
In vitro analysis 208 
 209 
The eight monoplex real-time PCR assays (i.e. IMPa, IMPb, IMPc, NDM, VIM, KPC, OXA-48 and GFP) 210 
were performed in 96-well plates with PCR mixes added in rows; DNA extracts were tested in column 211 
1 to 10, while column 11 and 12 were used to test extraction and positive controls respectively. The 212 
time necessary to complete PCR amplification and melt curve analysis was approx. 40min. Testing of 213 
undiluted DNA extracts resulted in strong PCR inhibition (as revealed by absence of- or delayed GFP 214 
amplification), consequently 1:20 dilutions were prepared prior to testing.  Formation of primer dimers 215 
was observed with the NDM assay, therefore oligonucleotide sequences were reviewed in silico and 216 
concentrations decreased in vitro to improve results (Table 2). 217 
 218 
DNA extracts of Escherichia coli NCTC 13476 (IMP), Klebsiella pneumoniae NCTC 13440 (VIM-1), 219 
Klebsiella pneumoniae NCTC 13443 (NDM-1), Klebsiella pneumoniae NCTC 13438 (KPC-3) and 220 
Klebsiella pneumoniae NCTC 13442 (OXA-48) were mixed to generate all possible target combinations 221 
(for simplicity only IMPa among the three IMP primer sets was included in this analysis). In all cases, 222 
the assay successfully detected all the carbapenemases present in the reaction mix, regardless of if 223 
only one or all five were present simultaneously (Supplementary data). 224 
 225 
Melt-curve analysis was used to confirm positive results by comparing dissociation curves to that of the 226 
relevant positive control. Minor Tm variations were observed for NDM, VIM, KPC, OXA-48-like and GFP 227 
(0.15 < St Dev < 0.30), while greater differences were noted with the three IMP monoplexes (0.49 < St 228 
Dev < 0.62).  229 
 230 
The expected result was initially obtained for 203 of the 204 previously characterised isolates. Klebsiella 231 
pneumoniae SACU 27698 was meant to be negative for the “big five” carbapenemases, instead it 232 
produced unequivocal amplification with IMPa (Ct = 17.49) and IMPb (Ct = 30.49) primer sets and 233 
melting curves consistent with those of E. coli NCTC 13476 and S. marcescens SACU 1212 (i.e. IMPa 234 
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and IMPb positive controls). Further analysis with in-house block-based PCR confirmed presence of 235 
IMP metallo- -lactamase, while Whole Genome Sequencing (WGS) by MiSeq (Illumina) characterised 236 
it as IMP-4 (data not shown). Indeed, the newly designed assay provided the expected result for all 204 237 
tested isolates (100% sensitivity and specificity) including those carrying two “big five” carbapenemases 238 
simultaneously. Cross-reaction with the other resistance markers present in the above mentioned 239 
isolates was not observed. 240 
 241 
Overall, amplification results produced mean Ct values of ca. 16 and Standard Deviation (SD) values 242 
between 0.88 and 1.45 (Table 3). Among the 40 isolates carrying IMP markers, 36 gave positive results 243 
with two of the three IMP primer sets used (i.e. a strong result in the expected Ct range and a weak 244 
result with Ct > 25 respectively). IMP alleles from part A of the Clustal generated tree gave strong IMPa 245 
results and weak IMPb results, alleles in part B gave strong IMPb results and weak IMPc results, while 246 
alleles in part C of the tree gave IMPc strong results and weaker IMPb results (Supplementary data). 247 
Four IMPs of which three IMP-13, were only amplified by one set of primers. 248 
    249 
 250 
Discussion  251 
 252 
We describe here the design and validation of an array of monoplex real-time PCRs optimised for the 253 
QuantStudio 6-flex platform (ThermoFischer Scientific) to rapidly detect and differentiate the “big five” 254 
carbapenemases, (i.e. IMP, NDM, VIM, KPC and OXA-48) from Enterobacteriales and non-fermenter 255 
Gram-negative isolates. A rational approach that took into account all the relevant allele sequences 256 
available from the Beta-Lactamase Database (as of December 2018) was applied in silico to design 257 
specific primers and to then predict whether they would also detect those allele variants that were not 258 
available to the authors for in vitro testing. A wide collection of previously characterised Gram-negative 259 
isolates was then tested in vitro to fully validate the newly designed monoplexes. An assay targeting 260 
the gfp [14] was simultaneously tested as an internal control to discount inhibition. 261 
 262 
As resistance markers (especially IMP in this case) evolve rapidly causing emergence of new allele 263 
variants, SYBR Green chemistry combined with melting curve analysis in monoplex PCR reactions was 264 
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chosen over multiplexing with primers and probes. Newly described SNPs in primers and/or probe 265 
binding sites would potentially result in assays having to be redesigned and then revalidated. This is 266 
time consuming and costly. The absence of probes in this assay reduces the number of binding sites 267 
from three to two and consequently the likelihood that a newly described SNP falls into them. If indeed 268 
a new SNP is identified in either of the two primer binding sites and it is decided that they need to be 269 
redesigned, the use of separate monoplexes allows to limit the revalidation to just the affected monoplex 270 
instead of having to perform a major revalidation like when a multiplex approach is used. Furthermore, 271 
the use of separate monoplexes provides greater flexibility to combine testing of different panels of 272 
targets if the need arises: one or more of the monoplexes described here could be quickly replaced with 273 
others validated separately to detect different resistance markers (e.g. GIM, SIM, SPM, IMI, etc) without 274 
the need to perform any further validation on the entire assay panel. 275 
 276 
The in silico analysis showed that this assay should be able to detect all the IMP, NDM, VIM and KPC 277 
variants described as of December 2018. Among the OXA-48-like group, OXA-54 and OXA-535, 278 
described in the chromosome of Shewanella species [15, 16] and OXA-436 identified on a plasmid in 279 
Enterobacter species, Citrobacter species and K. pneumoniae in Denmark [17] are unlikely to be 280 
detected.   281 
 282 
The in vitro experiments proved the assay to be 100% sensitive and specific on a large panel of 283 
previously characterised isolates available to the authors. As stated by Lund et al. (2018), assays are 284 
often validated using a limited selection of target variants that are available locally; furthermore, testing 285 
high numbers of unsequenced isolates might simply result in redundant analysis of a small number of 286 
variants which then provides little indication about the actual sensitivity and specificity of a particular 287 
assay. These issues were addressed in this study by applying a robust in silico approach to confidently 288 
predict amplification of those variants that were not available for in vitro testing and by then including 289 
(where possible) isolates where the “big five” allele variant had previously been characterised (i.e. by 290 
Sanger sequencing  and/or by WGS).  291 
 292 
Interpretation of melting profiles can be problematic when dissociation curves do not overlap with that 293 
of the positive control. This was often observed with isolates carrying IMP genes as a likely 294 
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consequence of high sequence variability of the IMP PCR products. Nevertheless,  when an IMP allele 295 
was present, more than one primer set was often able to detect it (usually two primers sets, one 296 
producing a strong result with Ct between 14 and 18, and another producing Ct > 18) allowing confident 297 
identification of true positives. It is noteworthy that variations in Tm results were observed also for those 298 
PCR products that were not meant to contain any SNP (e.g. KPC and GFP) therefore it seems that the 299 
actual Tm value cannot be reproducibly obtained by the PCR platform between different PCR runs. A 300 
Tm standard deviation of 0.20 was calculated for the GFP amplified fragment (which is identical in every 301 
PCR run) and this value could be considered as an indication of the Tm uncertainty of measurement 302 
intrinsic to this procedure. Different Tm values were also noted for VIM alleles, however in this case, it 303 
was due to VIM-7 being quite different (only 81% nucleotide identity with VIM-1), with a Tm of approx. 304 
84°C compared to Tm of approx. 81°C for the remaining VIM alleles. This was consistently observed 305 
and was actually helpful to differentiate between VIM-7 and the other VIM alleles. 306 
 307 
In at least one instance, the assay provided more sensitive and reliable results than standard phenotypic 308 
analysis: K. pneumoniae SACU 27698 previously characterised as negative for the “big five” 309 
carbapenemases, was instead found to be IMP positive and later characterised by WGS to carry IMP-310 
4. This result triggered an investigation that identified the above isolate as part of a cluster involving five 311 
patients (data not shown) which clearly proves the added value of the here described real time PCR 312 
assay. Retrospective analysis on the isolate showed that combination disks did not to show metallo- -313 
lactamase activity (i.e. only 2 mm difference between the meropenem and the meropenem/DPA disks) 314 
while the MP/MPI double-ended strip provided a weakly positive result (MIC ratio = 12). With this in 315 
mind, it was decided to modify the SACU approach for investigation of carbapenemases. The real time 316 
PCR assay described here became the first line method to investigate presence of the “big five” 317 
carbapenemases. Positive PCR results are reported immediately without performing further analysis, 318 
however as negative PCR results cannot completely exclude presence of a carbapenemase, further 319 
investigations need to be performed. As already mentioned, new “big five” allele variants might not be 320 
detected by this assay or a carbapenemase not included in this assay (e.g. GIM, SIM, SPM, etc) could 321 
be present. Finally, novel carbapenemases, not known as yet, would equally not be detected.  322 
Therefore, all PCR negative isolates are tested with combination disks and double ended strips to 323 
phenotypically exclude both carbapenemase and Extended Spectrum ß-lactamase (ESBL) activity 324 
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before negative results are reported. In those cases where carbapenemase activity is observed despite 325 
a negative PCR results, alternative methods (such as sequence analysis) would be applied to 326 
investigate the cause of the resistant phenotype.  327 
 328 
In certain cases, “big five” variants detected by this assay might actually confer either weak or 329 
undetectable level of carbapenemase resistance. Indeed, KPC-14 and KPC-28 have been 330 
demonstrated to have reduced carbapenemase activity [19] while OXA-163, OXA-247 and OXA-405 331 
have been shown to have no carbapenemase activity [20, 21] due to amino acid deletions in the active 332 
site. Isolates carrying these variants are likely to generate discrepant PCR and phenotypic results thus 333 
further testing (e.g. sequence analysis of the “big 5” variant) should be performed.  In particular, KPC-334 
28 has also been characterised to have an amino acid substitution (i.e. H274Y) causing a 50-fold 335 
increase in ceftazidime hydrolysis and consequently high MIC to ceftazidime/avibactam, an effective 336 
antimicrobial option for KPC producing bacteria [19].  337 
 338 
The assay described herein allows testing of 10 isolates at a time (plus extraction control and positive 339 
control) using 96-well plates. Given the short PCR running time (ca. 40 min), DNA could be extracted 340 
simultaneously from a greater number of isolates to allow a quick second PCR experiment to be 341 
prepared while the first is running; up to 20 isolates could be then tested in less than 90 min. 342 
Alternatively, for high through put 384-well plates may be used, allowing up to 46 strains (plus controls) 343 
to be tested simultaneously. The assay was deemed easy to perform by members of staff with little or 344 
no experience with real-time PCR and melt-curve analysis. Importantly, the real time PCR assay 345 
allowed unequivocal result interpretation even when more than one “big five” carbapenemase 346 
resistance marker was present. Finally, the new algorithm improved the reference service by reducing 347 
the time necessary to report positive results and at the same time reducing the risk of reporting false-348 
negative results. 349 
 350 
In summary the assay was easily implemented, allowed faster and more reliable positive results than 351 
previously obtained by SACU to be available for clinicians and infection control specialists. The potential 352 
wider benefits of the assay include reducing costs to the hospital from keeping potential positive patients 353 
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in side rooms, inappropriate therapy of positive patients and increased screening costs because of 354 
delays in positive results. 355 
 356 
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Table 1. Summary of primer sets used in this study (FP = Forward Primer; RP = Reverse Primer; 456 
ambiguities are underlined; * VIM and VIM-7 tested in the same tube). 457 
 458 
Primer 
set 
Target Name Sequence (5′→3′) Amplicon 
(bp) 
Reference 
1 IMP(a) 
IMPa_FP TGACGCAAATDTAGAAGCTTGGC 
101 This study 
IMPa_RP CRTCTCCARCTTCACTGTGAC 
2 IMP(b) 
IMPb_FP GAYGCCTATCTRATTGACACTCC 
79 This study 
IMPb_RP TATARCCGCGCTCMACAAACCA 
3 IMP(c) 
IMPc_FP KGAYGCAAATTTAGAAGCTTGGCCA 
142 This study 
IMPc_RP CCCTTTAACAGCCTGYTCCCA 
4 NDM 
NDM_FP CAACTTTGGCCCGCTCAAGG 
100 This study 
NDM_RP GCAGCCACCAAAAGCGATGT 
5* 
VIM 
VIM_FP CGAAAAACACAGCGGCMCTTCT 
73 This study  
VIM_RP GTGGAGACTGCACGCGTTAC 
  VIM-7 
VIM-7_FP GGTGGCTGTGCAGTTCATGAG 
122 This study 
VIM-7_RP ACGACCTCTGCTTCCGGATAC 
6 KPC 
KPC_FP CCACTGGGCGCGCACCTATT 
51 This study 
KPC_RP TGTTAGGCGCCCGGGTGTAG 
7 OXA-48-like 
OXA-48_FP CTGGTGGGTYGGTTGGGTTGA 
89 This study 
OXA-48_RP GCAGCCCTAAACCATCCGATGT 
8 GFP 
GFP_FP CCTGTCCTTTTACCAGACAACCA 
76 [14] 
GFP_RP GGTCTCTCTTTTCGTTGGGATCT 
  459 
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Table 2. Final concentration of primers used in this study (* VIM and VIM-7 tested in the same tube). 460 
Primer  
set Target 
Primer  
Name 
Final Conc. 
[nM] 
1 IMPa 
IMP(a)_FP 500 
IMP(a)_RP 500 
2 IMPb 
IMP(b)_FP 500 
IMP(b)_RP 500 
3 IMPc 
IMP(c)_FP 500 
IMP(c)_RP 500 
4 NDM 
NDM_FP 300 
NDM_RP 300 
5* 
VIM 
VIM_FP 400 
VIM_RP 400 
VIM-7 
VIM7_FP 100 
VIM7_RP 100 
6 KPC 
KPC_FP 500 
KPC_RP 500 
7 OXA-48-like 
OXA-48_FP 400 
OXA-48_RP 400 
8 GFP 
GFP_FP 300 
GFP_RP 300 
 461 
Table 3. Summary of Cycle threshold (Ct) and melting temperature (Tm) results for the primer sets 462 
used in this study (* VIM and VIM-7 tested in the same tube; ** only one strain containing VIM-7 was 463 
available for testing, consequently Min, Max and SD were not calculated). 464 
 465 
Primer  
set 
Target 
Ct Tm (°C) 
Min Mean Max SD Min Mean Max SD 
1 IMPa 14.67 16.73 20.35 1.43 76.92 77.74 78.47 0.49 
2 IMPb 14.43 16.66 18.94 1.45 75.13 76.31 77.21 0.77 
3 IMPc 14.88 16.06 16.98 0.88 76.92 77.51 78.06 0.62 
4 NDM 13.73 16.41 18.83 0.99 84.61 84.86 85.58 0.21 
5* 
VIM 14.11 16.09 18.23 0.95 80.43 80.73 81.07 0.15 
      VIM-7** - 15.49 - - - 84.12 - - 
6 KPC 13.52 16.81 18.50 1.13 82.90 83.40 83.83 0.30 
7 OXA-48-like 13.63 16.16 18.60 1.21 78.05 78.26 78.78 0.18 
8 GFP 21.36 23.36 24.28 0.44 77.51 77.77 78.83 0.20 
 466 
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Figure 1. Clustal Omega generated tree of the IMP alleles available from the Beta-Lactamase 467 
DataBase. 468 
 469 
